title: [Experience of the treatment for clinical Stage-1 seminoma over a period of 10 years].
abstract: OBJECTIVE
  Patients with clinical stage I seminoma accounts for 70%-80% of patients with this disease. This study was to analyze the relationship between different therapeutic methods and the prognosis of this disease.
  
  
  METHODS
  The data of all patients with clinical Stage I seminoma treated by multi-disciplinary approach from 1999 to 2008 in Sun Yat-sen University Cancer Center were analyzed. The patients were divided into 3 groups based on the treatment they received after orchiectomy: 30 patients treated with chemotherapy, 8 with radiotherapy, and 20 under surveillance. The prognosis of different treatment groups was evaluated.
  
  
  RESULTS
  Among the 58 patients with stage I seminoma, 57 were followed up successfully. The median follow-up time was 50 months (range, 8-115 months). No relapse or metastasis was seen in the chemotherapy group. One patient relapsed in the radiotherapy group. Four patients had metastasis of retroperitoneal lymph node in the surveillance group. The disease-free survival was higher in the chemotherapy group than that in the surveillance group (P=0.005). There was no significant difference in the relapse-free survival between the surveillance group and the radiotherapy group (P=0.364).
  
  
  CONCLUSIONS
  Chemotherapy is a safe and effective treatment for patients with Stage-1 seminoma after radical orchidectomy.
authors.affiliation: State Key Laboratory of Oncology, South China,Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Xue-Qi
authors.initials: XQ
authors.lastname: Zhang
authors.forename: Zhuo-Wei
authors.initials: ZW
authors.lastname: Liu
authors.forename: Fang-Jian
authors.initials: FJ
authors.lastname: Zhou
authors.forename: Hui
authors.initials: H
authors.lastname: Han
authors.forename: Zi-Ke
authors.initials: ZK
authors.lastname: Qin
authors.forename: Yun-Lin
authors.initials: YL
authors.lastname: Ye
authors.forename: Yong-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Hou
authors.forename: Zhi-Ling
authors.initials: ZL
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005047:Etoposide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009919:Orchiectomy / Q000379:methods; D012189:Retrospective Studies; D018239:Seminoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin